Xhale
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | Series A | |
N/A | N/A | Series B | |
$1.7m | Grant | ||
N/A | $16.0m | Series C | |
$620k | Grant | ||
N/A | $4.6m | Debt | |
Total Funding | AUD28.3m |
Related Content
Recent News about Xhale
EditXhale, Inc. specializes in developing advanced breath-based medical technologies aimed at enhancing patient monitoring and ensuring medication adherence. The company operates in the healthcare sector, focusing on personalized medicine and point-of-need monitoring solutions. Xhale serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and clinical trial organizations. Its business model revolves around creating novel patient-centric solutions that address unmet needs in the medical field. Xhale generates revenue through the sale of its innovative monitoring systems and related services, which help improve patient outcomes and streamline clinical trials. The company's management team boasts extensive experience and a proven track record of success, driving the firm’s commitment to quality, innovation, and excellence.
Keywords: breath-based technology, patient monitoring, medication adherence, personalized medicine, healthcare innovation, clinical trials, pharmaceutical compliance, real-time monitoring, medical devices, patient-centric solutions.